Aspira Pathlab & Diagnostics Limited
BSE: ASPIRA · Healthcare Service Provider
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Aspira Pathlab & Diagnostics Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aspira Pathlab and Diagnostics Limited is an Indian healthcare provider offering comprehensive pathology and radiology services. The company operates through a hub-and-spoke model, focusing on preventive healthcare and routine diagnostic testing for individuals, corporates, and insurers.
Business Model
The company generates revenue by providing diagnostic services including clinical chemistry, hematology, molecular biology, and advanced imaging. It leverages a network of diagnostic centers and collection points to serve a diverse client base.
Management Commentary
Management is focused on enhancing operational efficiency through the integration of automated laboratory technologies and digital health platforms. The company continues to expand its diagnostic footprint within the Mumbai Metropolitan Region.
Growth Outlook
Growth is driven by the expansion of the hub-and-spoke diagnostic network and ongoing investments in digital health integration. The company aims to improve accessibility and streamline reporting processes to capture a larger share of the preventive healthcare market.
Key Risks
- Regulatory Compliance. Changes in healthcare regulations and diagnostic licensing requirements could impact operational costs and service delivery.
- Intense Market Competition. The diagnostic sector in India is highly fragmented and competitive, which may exert pressure on pricing and profit margins.
- Technological Obsolescence. Failure to keep pace with rapid advancements in laboratory automation and diagnostic technology could lead to a loss of market share.
- Geographic Concentration. Heavy reliance on the Mumbai Metropolitan Region exposes the company to localized economic or operational disruptions.
Start your research today
Unlock AI insights, financials, peers and live data on Aspira Pathlab & Diagnostics Limited and 5,000+ companies — free.
Peers · Healthcare Service Provider
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Aspira Pathlab & Diagnostics LimitedASPIRA | ₹137 Cr | — | — | — | 5.8% | — | — | +92.3% |
Suraksha Diagnostic Ltd.SURAKSHA | ₹1,851 Cr | 50.02 | 17.47 | 22.5% | 32.7% | 15.8% | 18.6% | +17.7% |
Krsnaa Diagnostics Ltd.KRSNAA | ₹1,817 Cr | 18.46 | 8.75 | 10.2% | 32.5% | 10.5% | 13.3% | -28.2% |
3B BlackBio Dx Ltd3BBLACKBIO | ₹1,229 Cr | 25.08 | 14.76 | 54.3% | 52.8% | 19.0% | 24.1% | +18.1% |
One Global Service Provider LimitedONEGLOBAL | ₹1,062 Cr | 13.88 | 10.52 | 161.6% | 19.4% | 69.4% | 92.5% | +93.2% |
Gaudium IVF and Women Health LimitedGAUDIUMIVF | ₹857 Cr | — | — | — | 36.0% | — | — | — |
As of Mar 2026
Financials
Aspira Pathlab & Diagnostics Limited
BSE: ASPIRA · Healthcare Service Provider
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Aspira Pathlab & Diagnostics Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aspira Pathlab and Diagnostics Limited is an Indian healthcare provider offering comprehensive pathology and radiology services. The company operates through a hub-and-spoke model, focusing on preventive healthcare and routine diagnostic testing for individuals, corporates, and insurers.
Business Model
The company generates revenue by providing diagnostic services including clinical chemistry, hematology, molecular biology, and advanced imaging. It leverages a network of diagnostic centers and collection points to serve a diverse client base.
Management Commentary
Management is focused on enhancing operational efficiency through the integration of automated laboratory technologies and digital health platforms. The company continues to expand its diagnostic footprint within the Mumbai Metropolitan Region.
Growth Outlook
Growth is driven by the expansion of the hub-and-spoke diagnostic network and ongoing investments in digital health integration. The company aims to improve accessibility and streamline reporting processes to capture a larger share of the preventive healthcare market.
Key Risks
- Regulatory Compliance. Changes in healthcare regulations and diagnostic licensing requirements could impact operational costs and service delivery.
- Intense Market Competition. The diagnostic sector in India is highly fragmented and competitive, which may exert pressure on pricing and profit margins.
- Technological Obsolescence. Failure to keep pace with rapid advancements in laboratory automation and diagnostic technology could lead to a loss of market share.
- Geographic Concentration. Heavy reliance on the Mumbai Metropolitan Region exposes the company to localized economic or operational disruptions.
Start your research today
Unlock AI insights, financials, peers and live data on Aspira Pathlab & Diagnostics Limited and 5,000+ companies — free.
Peers · Healthcare Service Provider
As of Mar 2026